Shares of Organogenesis Holdings Inc (NASDAQ: ORGO) surged 10.54% in after-hours trading on Thursday following the release of its impressive third-quarter earnings report and an optimistic outlook for the full year 2025.

The regenerative medicine company reported Q3 net product revenue of $150.5 million, representing a 30.6% increase from the same period last year and surpassing analyst estimates of $134.10 million. The growth was primarily driven by a 31% increase in revenue from Advanced Wound Care products, which reached $141.5 million. Organogenesis also beat expectations on profitability metrics, with adjusted net income of $23.2 million and adjusted EBITDA of $30.1 million, both significantly higher than analyst projections.

Adding to the positive sentiment, Organogenesis updated its full-year 2025 guidance, projecting net product revenue between $500 million and $525 million. The company expects net income for the year to range from $8.6 million to $25.4 million, with adjusted EBITDA between $45.5 million and $68.3 million. CEO Gary S. Gillheeney, Sr. attributed the record revenue performance to strong execution of the company's strategy and leveraging customer relationships. He also expressed optimism about Organogenesis' positioning for 2026, citing the new CMS payment rule and the potential of its ReNu product in a new market opportunity.